Approved Treatments

Overview

Although there is no cure for neuromyelitis optica spectrum disorder (NMOSD) yet, there are approved treatments that can help manage the disease. Specifically, three immune-suppressing therapies — Enspryng, Soliris, and Uplizna — have been indicated for the treatment of anti-AQP4 positive NMOSD. Scroll down to learn more about each of these medications.

Enspryng

Enspryng (satralizumab-mwge) was approved by the U.S. Food and Drug Administration in August 2020. It is given as an under-the-skin injection for the prevention of NMOSD attacks. It suppresses the immune response by targeting the interleukin-6 receptors and blocking IL-6 signaling.

Learn more

Soliris

Soliris (eculizumab) was the first treatment approved by the FDA for NMOSD patients in 2019. Given through an infusion into the vein, it works by preventing the C5 protein from splitting, which leads to inflammation and the formation of the membrane attack complex.

Learn more

Ultomiris

Ultomiris (ravulizumab-cwvz) is an infusion therapy approved for adults with NMOSD who are positive for antibodies against the aquaporin 4 (AQP4) protein. It works to reduce the risk of disease relapses, or flares.

Learn more

Uplizna

Uplizna, given as an infusion into the vein, was approved by the FDA in June 2020. It works by targeting B-cells and inhibiting their antibody production, which lowers the risk of NMOSD attacks.

Learn more